Skip to main content

Table 2 Pre-transplant clinical history and transplantation of liver transplant recipients with NASH without pre-transplant DM

From: Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis

  NASH w/o DM Controls w/o DM p
BMI 30.1 ± 6.3 26.7 ± 5.6 <0.0001
Overweight (BMI 25–30) 871 (30.6 %) 4,608 (33.0 %) 0.0128
Obese (BMI > =30) 1,333 (46.9 %) 3,427 (24.6 %) <0.0001
Chronic obstructive pulmonary disease 29 (1.2 %) 164 (1.4 %) 0.47
Medically-treated hypertension 574 (23.4 %) 2,062 (17.2 %) <0.0001
Coronary artery disease 76 (3.1 %) 184 (1.5 %) <0.0001
Stroke 21 (0.8 %) 77 (0.6 %) 0.24
Peripheral vascular disease 24 (1.0 %) 108 (0.9 %) 0.73
Pulmonary embolism 8 (0.3 %) 45 (0.4 %) 0.72
Malignancy (solid organ or lymphoproliferative) 210 (7.2 %) 1,544 (10.9 %) <0.0001
Other solid organ transplants 7 (0.2 %) 106 (0.7 %) 0.0022
Primary liver malignancy 130 (4.5 %) 2,202 (15.4 %) <0.0001
TIPSS 300 (10.4 %) 1,073 (7.6 %) <0.0001
Transplantation    
Last MELD score 22.8 ± 8.5 22.2 ± 9.9 <0.0001
Heterotopic transplant 3 (0.1 %) 15 (0.1 %) 0.97
Transplant from a living donor 97 (3.3 %) 729 (5.1 %) <0.0001
Donor’s age 43.2 ± 17.4 41.4 ± 17.6 <0.0001
Donor’s history of DM 315 (11.2 %) 1,357 (10.1 %) 0.06
Procurement from a non-heart beating donor 137 (4.9 %) 572 (4.2 %) 0.13
Number of HLA mismatches with a donor 4.52 ± 1.15 4.55 ± 1.14 0.39
Immunosuppressants used at transplant:    
 Mycophenolates 2,275 (78.2 %) 10,943 (76.9 %) 0.14
 Tacrolimus 2,695 (92.6 %) 13,235 (93.0 %) 0.43
 Steroids 2,763 (94.9 %) 13,519 (95.0 %) 0.88
Rejection episode before discharge 166 (6.2 %) 999 (7.8 %) 0.0031
Post-transplant inpatient stay, days 16.0 ± 18.7 15.6 ± 19.9 0.0498
Total inpatient stay, days 20.7 ± 36.2 20.1 ± 29.2 0.16
Non-compliant in follow-up (ever) 104 (4.0 %) 764 (6.0 %) 0.0001
\